A132 THREE QUARTERS OF INFLAMMATORY BOWEL DISEASE PATIENTS ON MAINTENANCE INFLIXIMAB THERAPY IN CLINICAL REMISSION SHOW EVIDENCE OF MUCOSAL INFLAMMATION WITH ELEVATED FECAL CALPROTECTIN

Samankaltaisia teoksia

• Knowledge of Fecal Calprotectin and Infliximab Trough Levels Alters Clinical Decision-making for IBD Outpatients on Maintenance Infliximab Therapy
  Tekijä: Huang, Vivian W., et al.
  Julkaistu: (2015)
• A147 COMBINING INFLIXIMAB TROUGH LEVELS AND FECAL CALPROTECTIN LEVELS WITH CLINICAL DATA HAS THE POTENTIAL TO GUIDE CLINICAL DECISION-MAKING IN IMPROVING OUTCOMES FOR INFLAMMATORY BOWEL DISEASE PATIENTS ON MAINTENANCE INFLIXIMAB.
  Tekijä: Amin, A, et al.
  Julkaistu: (2018)
• A137 THERAPEUTIC DRUG MONITORING WITH INFLIXIMAB TROUGH LEVELS LEAD TO INCREASED INTERVENTION
  Tekijä: Stern, N C, et al.
  Julkaistu: (2018)
• A84 HIGH FECAL CALPROTECTIN LEVELS IN ULCERATIVE COLITIS PATIENTS IN CLINICAL REMISSION ARE ASSOCIATED WITH SPECIFIC CLINICAL AND DIETARY INTAKE PARAMETERS.
  Tekijä: Keshteli, A H, et al.
  Julkaistu: (2018)
• A142 INFLAMMATORY BOWEL DISEASE PATIENTS REQUIRE AN INCREASED ADALIMUMAB DRUG LEVEL TO SIMULTANEOUSLY ACHIEVE CLINICAL AND BIOLOGICAL REMISSION
  Tekijä: Cookson, T A, et al.
  Julkaistu: (2019)